Article Text

Download PDFPDF
Features of the transposed seasonality of the 2021 RSV epidemic in the UK and Ireland: analysis of the first 10 000 patients
  1. Damian Roland1,2,
  2. Thomas Williams3,
  3. Mark D Lyttle4,5,
  4. Robin Marlow4,
  5. Pia Hardelid6,
  6. Ian Sinha7,8,
  7. Olivia Swann3,9,
  8. Abigail Maxwell-Hodkinson8,
  9. Steve Cunningham10,11
  1. 1Paediatric Emergency Medicine Leicester Academic (PEMLA) Group, Leicester Royal Infirmary, Leicester, UK
  2. 2SAPPHIRE Group, Health Sciences, University of Leicester, Leicester, UK
  3. 3Child Life and Health, University of Edinburgh, Edinburgh, UK
  4. 4Emergency Department, Bristol Royal Hospital for Children, Bristol, UK
  5. 5Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK
  6. 6Great Ormond Street Institute of Child Health, University College London, London, UK
  7. 7Alder Hey Children's NHS Foundation Trust, Liverpool, UK
  8. 8Division of Child Health, University of Liverpool, Liverpool, UK
  9. 9Department of Paediatric Infectious Diseases and Immunology, Royal Hospital for Children, Glasgow, UK
  10. 10Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK
  11. 11Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK
  1. Correspondence to Professor Damian Roland, Leicester Royal Infirmary, Leicester, UK; dr98{at}leicester.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Non-pharmaceutical interventions (NPIs) introduced globally to limit the spread of SARS-CoV-2 led to disruption of the typical respiratory syncytial virus (RSV) seasonality.1 Studies examining the resurgence of RSV have been limited by sample size and lack of information on secondary care episodes and clinical features. The BronchStart study is a prospective multicentre cohort study. Paediatric emergency departments (PED) within PERUKI (Paediatric Emergency Research in the UK and Ireland) submit data on all children under 2 years of age who visit a PED with symptoms of an acute lower respiratory tract infection (diagnosed as bronchiolitis, lower respiratory tract infection or first episode of acute wheeze). Follow-up information is submitted 7 days later and study data are made available on a live online dashboard hosted by Microreact.2

We present initial data for 10 347 infants and children from 44 study sites for the period 1 June–5 December 2021. The 2021 RSV epidemic in the UK has finished with infections having peaked in August (figure 1A). Comparing the age distribution of hospitalised infants <12 months with that of previous years at two large paediatric centres participating in BronchStart (Leicester Children’s Hospital and Bristol Royal Hospital for Children), we observed a similar age distribution (figure 1B). This suggests either reduced community exposure to RSV during the 15 months preceding the start of the season did not result in a clinically significant lack of protective maternal antibody transfer to those <3 months of age or the NPIs introduced did not …

View Full Text

Footnotes

  • Twitter @damian_roland, @mdlyttle

  • Collaborators Meriel Tolhurst-Cleaver, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England; Stuart Hartshorn, Birmingham Children's Hospital, Birmingham, England; Jessica Watson, Bolton NHS Foundation Trust, Bolton, England; Roisin Begley, Bristol Royal Hospital for Children, Bristol, England; Sakura Hingley, Manali Dutta and Gemma Ramsden, Chelsea and Westminster NHS Foundation Trust, London, England; Eleanor Ryan, Children's Health Ireland at Crumlin, Dublin, Ireland; Sheena Durnin and Stanley Koe, Children's Health Ireland at Tallaght, Dublin, Ireland; Steve Brearey, Countess of Chester NHS Foundation Trust, Chester, England; Darren Ranasinghe, Croydon University Hospital, Croydon, England; Mudiyur Gopi, East Cheshire NHS Trust, England, Macclesfield, England; Patrick Aldridge and Vicky Owens, Frimley Park Hospital, London, England; Simon Richardson, Hull Royal Infirmary, Hull, England; David Hartin, Ipswich Hospital, Ipswich, England; Jiske Steensma and Sahana Rao, John Radcliffe Hospital, Oxford, England; Damian Roland, Leicester Royal Infirmary, Leicester, England; Jo Tillett and Simon Dowson, Leighton Hospital, Crewe, England; Adebayo Da Costa and Alfred Sime, Medway Hospital NHS Foundation Trust, Gillingham, England; Claire Kirby, Newham University Hospital, Newham, England; Adam Lawton, North Middlesex Hospital, London, England; Ruth Wear and Christopher Gough, Nottingham University Hospitals NHS Trust, Nottingham, England; Sharryn Gardner and Craig Rimmer, Ormskirk District General Hospital, Ormskirk, England; Heather Deall, Poole Hospital, Poole, England; Sharon Hall, Queen Elizabeth Hospital, Woolwich, London, England; Catriona Middleton, Royal Aberdeen Children's Hospital, Aberdeen, Scotland; Emily Walton and Friyana Dastur Mackenzie, Royal Alexandra Children's Hospital, Brighton, England; Manish Thakker, Royal Berkshire NHS Foundation Trust, Reading, England; Gisela Robinson and Graham Johnson, Royal Derby Hospital, Derby, England; Steve Foster, Royal Hospital for Children, Glasgow, Glasgow, Scotland; Jen Browning and Lynsey Rooney, Royal Hospital for Children & Young People, Edinburgh, Edinburgh, Scotland; Lorna Bagshaw, Royal Wolverhampton NHS Trust, Wolverhampton, England; Seb Gray, Salisbury NHS Foundation Trust, Salisbury, England; Sally Gibbs, Sheffield Children's NHS Foundation Trust, Sheffield, England; Niall Mullen, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, England; Jane Bayreuther, Southampton Children's Hospital, Southampton, England; Heather Jarman, St George's Hospital, London, London, England; Clare O'Leary, St Helens & Knowsley NHS Trust, Rainhill, England; Raine Astin-Chamberlain, The Royal London, London, England; Lawrence Armstrong and Joanne Mulligan, University Hospital Crosshouse, Kilmarnock, Scotland; Sophie Keers, University Hospital Lewisham, London, England; Richard Burridge, Watford General Hospital (West Herts NHS Trust), Watford, England; Sarah Wilson, Wexham Park Hospital, Slough, England; Amutha Anpananthar, Whipps Cross Hospital, London, England; David Lacy, Wirral University NHSFT, Birkenhead, England.

  • Contributors TW, IS, OS: conceptualisation, methodology, writing—original draft preparation, writing—review and editing. MDL: conceptualisation, methodology, project administration, software, writing—original draft preparation, writing—review and editing. SC, DR: conceptualisation, methodology, project administration, writing—original draft preparation, writing—review and editing. AM-H: conceptualisation, methodology, writing—review and editing. PH: methodology, writing—review and editing. RM: methodology, data management.

  • Funding This study received financial and administrative support from the Respiratory Syncytial Virus Consortium in Europe (RESCEU) and Paediatric Emergency Research in the UK and Ireland (PERUKI). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 116019. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The results reported herein reflect only the authors’ view and not of the European Commission. As such, the EC is not responsible for any use that may be made of the information contained in this publication.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.